Related Experiment Video

Updated: Feb 20, 2026

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

15.3K

T cell leukemia control via Ras-Raf pathway inhibition with peptides

G H Marin1, A Rebollo2, H Bruzzoni-Giovanelli3

  • 1National University of La Plata - Pharmacology Department-CONICET

Journal of Medicine and Life
|October 28, 2017
PubMed
Abstract

Insights

Novel peptides targeting the RAS-RAF-MEK-ERK pathway significantly improved survival in mice with aggressive T lymphoid leukemia. These peptides offer a promising new therapeutic strategy for lymphoproliferative diseases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The RAS-RAF-MEK-ERK pathway is a key target in anticancer therapy.
  • Tumor resistance can arise from N-Ras hyperactivation, necessitating novel therapeutic strategies.
  • Peptides designed to inhibit Ras/Raf interaction exhibit pro-apoptotic properties.

Purpose of the Study:

  • To evaluate the anti-tumoral efficacy of WO2015001045 A2 peptides.
  • To assess the impact of these peptides on survival in a spontaneous leukemia model.

Main Methods:

  • BALB/c mice with LB leukemia were randomly assigned to control (placebo) or treatment groups.
  • Treatment involved daily administration of 3 mg/kg of peptide for 30 days.
  • Survival rates and malignant T cell presence in organs were monitored.

Main Results:

  • 100% survival in the treatment group by day 15 versus 24% in the control group.
  • Average survival increased from 15.48 days (control) to 20.27 days (treated).
  • Reduced malignant T cell infiltration was observed in bone marrow, spleen, and lymph nodes of treated mice.

Conclusions:

  • WO2015001045 A2 peptides significantly improve survival in a murine model of spontaneous T lymphoid leukemia.
  • These peptides represent a potential therapeutic option for controlling malignant lymphoproliferative diseases.
Keywords:
cancercontrolleukemiamicepeptides

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

832

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.5K